Quantcast
Last updated on April 17, 2014 at 10:21 EDT

Latest UCB Inc. Stories

2011-11-01 09:00:00

ATLANTA, Nov. 1, 2011 /PRNewswire/ -- In honor of Epilepsy Awareness Month, global biopharmaceutical company UCB, Inc. is enlisting the help of its Epilepsy Advocates to "start a revolution," by inspiring people impacted by epilepsy to speak out about the condition. As part of this effort, UCB will roll out a series of initiatives, including a nationwide grassroots campaign called "Army of Advocates" and two new Epilepsy Advocate Radio shows featuring a representative from HealthyWomen --...

2011-10-28 09:00:00

ATLANTA, Oct. 28, 2011 /PRNewswire/ -- UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is marking the 2011 American College of Gastroenterology (ACG) meeting in Washington, D.C. by reinforcing its commitment to improving the lives of patients with Crohn's disease. At this year's ACG meeting, a large body of UCB data will highlight the potential role of inflammatory biomarkers in treatment of moderate to severe Crohn's disease. "ACG is an...

2011-09-28 06:45:00

ATLANTA and RED BANK, N.J., Sept. 28, 2011 /PRNewswire/ -- Managing RA: The Strong Woman's Approach, is an online resource designed to educate and empower women living with rheumatoid arthritis (RA), launched today at HealthyWomen.org. There are 1.3 million Americans living with RA, and women are two to three times more likely to develop the disease than men. Managing RA: The Strong Woman's Approach provides practical solutions and exercise advice specifically designed to address some of...

2011-09-13 07:00:00

MORRISTOWN, N.J., Sept. 13, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. has launched Levetiracetam Extended-Release 500 mg and 750 mg tablets, the generic version of UCB, Inc.'s Keppra XR(®) following approval of its Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA). Watson has begun shipping the product today. Keppra XR(®) is indicated...

2011-06-09 11:16:00

ATLANTA, June 9, 2011 /PRNewswire/ -- UCB, Inc. today announced an agreement with the U.S. Department of Justice (DOJ) to resolve a previously disclosed government investigation into the marketing and promotion of Keppra®, an anti-epileptic prescription medicine. As previously reported, the issues that were the subject of this investigation occurred more than six years ago, and as recognized by the DOJ, UCB has cooperated fully with the United States since learning of the...

2011-05-31 08:45:00

BALTIMORE, May 31, 2011 /PRNewswire/ -- UCB announced findings of the first cost-effectiveness analysis of Vimpat® (lacosamide) as add-on therapy for adults with uncontrolled partial-onset seizures. The findings were presented at the 16th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting in Baltimore, MD, USA. Researchers used a simulated pharmaco-economic model to analyze standard anti-epileptic drug therapy with and without...

2010-11-30 09:00:00

ATLANTA, Nov. 30, 2010 /PRNewswire/ -- New data on UCB's anti-epileptic drug (AED) Vimpat® (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES), taking place at the San Antonio Convention Center in San Antonio, Texas from December 3 to 7. Data will also be presented on Keppra XR and the investigative epilepsy therapy, brivaracetam. Vimpat® tablets and injection were launched in the U.S. in May 2009 as an...

2010-11-22 11:03:00

ATLANTA, Nov. 22, 2010 /PRNewswire/ -- New stories and insights from the epilepsy community have been unveiled on EpilepsyAdvocate.com, including new interviews on "Women Succeeding with Epilepsy" and Epilepsy Advocate Radio. These programs represent UCB's continued commitment to the epilepsy community and seek to both empower patients and raise awareness about the condition. NEW WEBISODES FOR WOMEN! Two new video interviews are available featuring Epilepsy Advocates Amy Wyatt and...

2010-11-18 09:00:00

ATLANTA, Nov. 18, 2010 /PRNewswire/ -- UCB, Inc., a global leader in the research and development of medications to treat immunology disorders, today announced the winners of its 2010 UCB Rheumatoid Arthritis Family Scholarship Program for outstanding individuals affected by this condition. UCB is awarding 31 scholarships worth up to $10,000 to help deserving students seek personal growth through higher education. The scholarship winners include rheumatoid arthritis (RA) patients, as...

2010-11-09 09:30:00

ATLANTA, Nov. 9, 2010 /PRNewswire/ -- Today, UCB, Inc. celebrates the academic success of the 2010 UCB Family Epilepsy Scholarship recipients. Over the past 6 years, UCB has awarded more than 200 scholarships, totaling over $1 million, to people whose lives have been directly affected by epilepsy, including those with epilepsy, their caregivers and family members. Epilepsy is a common neurological condition that can affect anyone at anytime. In the United States, 1 in 100 people are...